• Trial(s) for Transplantation

    Study Objective Contact
    A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants [LCID Study Number: 2014-032] Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A Multi-Center, Randomized, Prospective Open- Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin (HCIG) in Orthotopic Liver Transplant Recipients [LCID Study Number: 2014-023] This purpose of this study is to test the safety of different doses of the investigational therapy Hepatitis C Immune Globulin (HCIG) when given to patients with Hepatitis-C (HCV) who undergo liver transplantation. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like 2 (LOXL2) in SUBJECTS WITH ADVANCED LIVER FIBROSIS but Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) GS-US-321-0105 [LCID Study Number: 2013-028] The purpose of this study is to see if the investigational drug, GS-6624, can reverse advanced liver fibrosis and prevent cirrhosis. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) in SUBJECTS WITH COMPENSATED CIRRHOSIS Secondary to Non-Alcoholic Steatohepatitis (NASH) GS-US-321-0106 [LCID Study Number: 2013-026] The purpose of this study is to see if simtuzumab can reverse liver scarring and heal cirrhosis. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma(HCC) [LCID Study Number: 2012-052] The purpose of this study is to see if sorafenib is a safe and effective treatment option for preventing Hepatocellular Cancer (HCC) from returning in “high risk” patients after transplantation. Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco.
    A Prospective Investigation Of Quality Of Life In Live Liver Donors [LCID Study Number: 2001-019] Questionnaire study of quality of life in live liver transplant donors Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A2ALL: Adult-to-Adult Living Donor Liver Transplant Cohort Study [LCID Study Number: 2011-011] The purpose of this study is to collect information about live donor transplant surgery, complications experienced after surgery, pain experience and how the donation surgery impacts quality of life after the surgery. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    An Observational Study to Assess Documentation of Hepatic Encephalopathy in Clinical Practice [LCID Study Number: 2015-006] This observational study is being done to find out how doctors describe hepatic encephalopathy episodes as part of their regular practice. ENROLLMENT BY INVITATION ONLY. Principal Investigator(s):
    Amir A. Qamar, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    Comparative Assessment of Effectiveness of Antiviral Therapies in Hepatitis C (CMPASS) [LCID Study Number: 2012-075] The purpose of this study is to get a better understanding of how patients with chronic Hepatitis C (HCV) are treated and how their disease is managed in the “real world”. Understanding how well available treatments for HCV work and how well patients are able to tolerate the medications will help guide doctors on how best to treat patients in the future. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    Impact of IL-28B Gene Polymorphism on Outcome of Patients Undergoing Liver Transplantation for Hepatitis C [LCID Study Number: 2012-073] The purpose of this study is to collect data on favorable donor-recipient pairing, grafts, genotypes and patient outcomes. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Fredric D. Gordon, MD.
    Integrated Tissue and Clinical Data Bank for Bile Duct Cancers [LCID Study Number: 2013-022] Very little is known about what causes bile duct cancers. It is hoped that by studying tissue samples and clinical information from patients with bile duct cancers together, researchers may learn about factors that cause these cancers. Principal Investigator(s):
    Roger Jenkins, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco.
    Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with or without Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 Hepatitis C Virus (HCV) Infection [LCID Study Number: 2013-027] The purpose of this study is to see if 3 investigational drugs (ABT-450/r/ABT-267, and ABT-333) taken with or without ribavirin is safe and able to reduce the amount of hepatitis C virus in the blood of patients with Hepatitis C. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
  • Make An Appointment

    (781) 744-2500
  • HRSA Award

    Health Resources and Services Administration (HRSA) Awards Lahey Clinic the Silver1 Medal of Honor for Organ Donation.